Solasia Pharma K.K.

4597

JP3436500007

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
26 ^JPY	+4.00%		+4.00%	-42.22%

Mar. 04	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI
Feb. 16	Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	CI

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX).

July 07, 2022

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX) on July 8, 2022.

Solasia Pharma K.K. (TSE : 4597) completed the acquisition of Episil oral liquid business from Camurus AB (publ) (OM : CAMX) on July 8, 2022.

Latest news about Solasia Pharma K.K.

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	Mar. 03	CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond	Feb. 15	CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited	Feb. 14	CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	Dec. 28	CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains	Nov. 13	MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	Nov. 13	CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index	23-09-18	CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-10	CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023	23-05-15	CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe	23-03-21	MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program	23-03-20	CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023	23-02-14	CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study	22-11-27	MT
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-25	CI
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.	22-11-21	CI
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-11-14	CI
Solasia Announces Summary of SP-04 PledOx Development Status	22-09-05	CI
Solasia Launches Anticancer Injection Darvias	22-08-23	MT
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022	22-08-15	CI
Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)	22-08-03	CI
Solasia Pharma K.K. announced that it has received Ã‘1.02 billion in funding from Nippon Kayaku Co., Ltd.	22-07-13	CI
Solasia Takes Over Episil Oral Liquid Business from Camurus	22-07-11	MT
Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (OM : CAMX).	22-07-07	CI
Solasia Pharma to Divest Sales Function for Two Chemotherapy-support Drugs to Lee's Pharmaceutical	22-07-01	MT

Chart Solasia Pharma K.K.

Duration

Period

More charts

Company Profile

Solasia Pharma K.K. is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The Company's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Solasia Pharma K.K.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26 JPY

Average target price

100 JPY

Spread / Average Target

+284.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SOLASIA PHARMA K.K.	-42.22%	30.07M
CSL LIMITED	-4.75%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals